

**Schmid, Johannes A., PhD, Associate Prof. – Curriculum Vitae 2024-09-25**

Medical University Vienna  
 Center for Physiology and Pharmacology,  
 Dept. of Vascular Biology and Thrombosis Research,  
 Schwarzschanerstr. 17, A1090 Vienna, Austria, Tel. +43 1 40160 31155  
 Email: [johannes.schmid@meduniwien.ac.at](mailto:johannes.schmid@meduniwien.ac.at)  
 Website: [www.meduniwien.ac.at/user/johannes.schmid](http://www.meduniwien.ac.at/user/johannes.schmid)  
 ORCID-ID: <http://orcid.org/0000-0002-6586-3507>

**Personal Data**

Date of Birth: 1966-07-11  
 Place of Birth: Mödling, Lower Austria  
 Nationality: Austria

**Education**

1990 - 1994 PhD-thesis at the Dept. of General and Experimental Pathology, University Vienna (now: Inst. of Pathophysiology, Med. Univ. Vienna), Topic: "Endocytosis and Transcytosis in Hepatocytes". Doctorate with distinction.  
 1984 - 1990 Studies of food technology and biotechnology at the University of Natural Resources and Life Sciences, Vienna.  
 1976 - 1984 Secondary school in Mödling, (with emphasis on foreign languages). Final examination with excellent success.  
 1972 - 1976 Elementary school in Wiener Neudorf, Lower Austria

**Career History**

02/2024 Full professorship in the field of Cardiovascular Medicine, Medical University of Vienna  
 06-08/2023 Panel leader for the evaluation of the faculty for medicine and dentistry of the Palacky Univ. of Olomouc  
 04/2022 Selected as one of three candidates for an internationally announced professorship for physiology/pathophysiology at the Med. Univ. of Graz  
 Since 10/2020 Head of the Inst. of Vascular Biology and Thrombosis Research, Med. Univ. Vienna  
 Since 2/2018 Speaker and coordinator for the 2<sup>nd</sup> funding period of the Special Research Program (SFB-F54; Cellular mediators linking inflammation and thrombosis)  
 9/2015 Ranked 2<sup>nd</sup> for a full-professorship at the Medical Univ. Vienna (for the field "Molecular Physiology").  
 Since 2/2014 Speaker of a Special Research Program (SFB-F54) of the Austrian Science Fund (FWF), coordinating a consortium of 10 groups of the Medical University of Vienna (Title: Cellular mediators linking inflammation and thrombosis)  
 4/2011 Ranked 2<sup>nd</sup> at an application for the position of a vice-rector for research at the University of Veterinary Medicine, Vienna  
 Since 7/2008 Associate Professor and Group Leader at the Medical University Vienna, Center for Physiology and Pharmacology.  
 8. 5. 2008 2<sup>nd</sup> Habilitation for Biochemistry at the Univ. of Natural Resources and Life Sciences, Vienna

9/2005 – 6/2008	Co-founder and Deputy Director of the Ludwig Boltzmann Institute for Cancer Research heading one of the research groups and serving as Chief Financial Officer
1/2004 – 9/2005	Research Assistant at the Dept. of Vascular Biology and Thrombosis Research, Univ. Vienna and Group Leader at the Competence Center "Bio Molecular Therapeutics"
Dec. 2004	Award of a comprehensive research grant for the foundation of a new "Ludwig Boltzmann Institute for Cancer Research" with a size of about 18 scientists (as co-applicant)
2/2003 – 1/2004	Sabbatical at the Yale University Medical School, Dept. of Immunobiology in the group of Sankar Ghosh (funded by a Max Kade Grant from the Austrian Academy of Sciences).
6. 6. 2002	Habilitation (University Lecture Qualification) for Vascular Biology at the Medical Univ. Vienna
9/2000 – 03/2003	Group Leader at the Competence Center "Bio Molecular Therapeutics (BMT)"
2/1998 – 9/2000	Research Assistant at the Dept. of Vascular Biology and Thrombosis Research, Univ. Vienna
10/1996 – 2/1998	Postdoctoral Fellowship at the Dept. of Vascular Biology and Thrombosis Research, Univ. Vienna (Research on activation of endothelial cells).
11/1994 - 10/1996	Postdoctoral Fellowship at the Novartis Research Institute, Vienna (Dept. of General Dermatology: Investigation of the effects of vitamin D <sub>3</sub> -metabolites on human keratinocytes).

#### Career-related Activities

8/1988 - 9/1988	Temporary employment at the Unilever Research Laboratory, Bedford, England, in co-operation with the Austrian Research Center, Seibersdorf.
2/1991 - 4/1991	Scientific investigations at the Research Institute of Scripps Clinic, La Jolla, California, USA.
2/1993 - 3/1993	Research at the Carnegie Mellon University, Pittsburgh, USA.
5/2000 – 6/2000	Short term fellowship at the European Advanced Light Microscopy Facility, localized at the EMBL Heidelberg, Germany

#### Further achievements

03/2010	Guest professorship: University of Salzburg, Austria, March 2010
04/2010	Guest professorship: National University of Science and Technology, Islamabad, Pakistan, April 2010
1994	Theodor-Körner-Award for natural sciences.
1989	Award of a scholarship for outstanding performance at the university.

#### Editorial board memberships

- Associate Editor of the journal *Molecular Cancer* (IF: 41.4)
- Associate Editor of *Frontiers in Cardiovascular Medicine* (Atherosclerosis and Vascular Medicine: IF: 5.8).
- Associate Editor Editor of the journal *Cells* (Section: Cell signaling IF: 7.7)

#### Memberships

- Austrian Association of Molecular Life Sciences and Biotechnology (OeGMBT)
- Austrian Society for Allergology and Immunology (OeGAI)
- European Atherosclerosis Society and Austrian Atherosclerosis Society
- Austrian Physiology Society

- Member of the Study group for equal treatment issues of the Med. Univ. Vienna: 2011 - 2013
- Member of the PhD Curriculum Committee of the Med. Univ. Vienna: 2011-2013

**Description of research interests and most important scientific achievements**

Current research interests focus on molecular and cellular links between inflammation, cardiovascular diseases and cancer with a special focus on NF-kappa B signaling, as well as interconnections with other signaling processes and networks. Various experimental systems are used, such as cell culture of primary and transformed cells, transgene mouse models, and analysis of human samples. Molecular and biochemical techniques are applied and complemented by high-end microscopy, cytometry and multiple omics-approaches (RNA- and ATAC-sequencing, DNA-methylation, proteomics, epigenomics) combined with professional bioinformatics and network analyses.

**Publications, talks and citations** (as per Sept 25<sup>th</sup> 2024)

100 publications, 74 lectures, 4 patents; [Pubmed-Link](#)

Total number of citations: 11839; h-index: 45 (based on Google Scholar, Sept 25th, 2024)

[http://scholar.google.at/citations?user=7kJu\\_MYAAAAJ](http://scholar.google.at/citations?user=7kJu_MYAAAAJ);

<http://orcid.org/0000-0002-6586-3507>; SCOPUS: h-index: 38, 8376 citations

**Top 10 Publications**

1. Mussbacher M, Derler M, Basilio J, Schmid JA: **NF-kappaB in monocytes and macrophages - an inflammatory master regulator in multitasking immune cells.** *Front Immunol* 2023, **14**:1134661. <https://doi.org/10.3389/fimmu.2023.1134661>
2. Beck S, Hochreiter B, Schmid JA: **Extracellular Vesicles Linking Inflammation, Cancer and Thrombotic Risks.** *Frontiers in Cell and Developmental Biology* 2022, **10**. <https://doi.org/10.3389/fcell.2022.859863>
3. Moser B, Hochreiter B, Basilio J, Gleitsmann V, Panhuber A, Pardo-Garcia A, . . . Schmid JA: **The inflammatory kinase IKK $\alpha$  phosphorylates and stabilizes c-Myc and enhances its activity.** *Mol Cancer* 2021, **20**(1):16. <https://doi.org/10.1186/s12943-021-01308-8>
4. Salzmann M, Bleichert S, Moser B, Mussbacher M, Haase M, Hoesel B, . . . Schmid JA: **I $\kappa$ B kinase 2 is not essential for platelet activation.** *Blood Adv* 2020, **4**(4):638-643. <https://doi.org/10.1182/bloodadvances.2019001044>
5. Mussbacher M, Salzmann M, Haigl B, Basilio J, Hochreiter B, Gleitsmann V, . . . Schmid JA: **Ikk2-mediated inflammatory activation of arterial endothelial cells promotes the development and progression of atherosclerosis.** *Atherosclerosis* 2020, **307**:21-31. <https://doi.org/10.1016/j.atherosclerosis.2020.06.005>
6. Mussbacher M, Salzmann M, Brostjan C, Hoesel B, Schoergenhofer C, Datler H, . . . Schmid JA: **Cell Type-Specific Roles of NF- $\kappa$ B Linking Inflammation and Thrombosis.** *Front Immunol* 2019, **10**:85. <https://doi.org/10.3389/fimmu.2019.00085>
7. Hoesel B, Schmid JA: **The complexity of NF- $\kappa$ B signaling in inflammation and cancer.** *Mol Cancer* 2013, **12**:86. <https://doi.org/10.1186/1476-4598-12-86>
8. Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, Starkl P, . . . Wagner O: **The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism.** *Cell Metab* 2012, **15**(6):813-826. <https://doi.org/10.1016/j.cmet.2012.04.023>
9. Ebner K, Bandion A, Binder BR, de Martin R, Schmid JA: **GMCSF activates NF-kappaB via direct interaction of the GMCSF receptor with I $\kappa$ B kinase beta.** *Blood* 2003, **102**(1):192-199. <https://doi.org/10.1182/blood-2002-12-3753>
10. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J: **Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis.** *J Exp Med* 1998, **188**(1):211-216. <https://doi.org/10.1084/jem.188.1.211>